Designing a large prevention trial: statistical issues
- PMID: 14716729
- DOI: 10.1002/sim.1716
Designing a large prevention trial: statistical issues
Abstract
Recent research in Alzheimer's disease (AD) is centred about the early detection and prevention of this disease. Several recent moderate size clinical trials targeted at high risk cohorts have been designed along this theme. There have been few attempts to design a large trial to prevent this disease in elderly individuals at low risk for the disease. The purpose of this paper is to suggest a framework for designing a simple, large AD prevention trial. This framework uses a discrete time hazard model for decreasing the incidence of AD when participants are randomly assigned to one or more active prevention agents or placebo. This design allows for differential incidence among participants due to age, family history, genetic disposition, and ethnicity. It takes into account the length of the follow-up period, participant mortality, drop-outs, drop-ins, and loss to follow-up. This framework is illustrated by PREADVISE, a recently initiated large add-on prevention trial investigating the use of anti-oxidants for preventing AD among men enrolled in a even larger prostate cancer prevention study, SELECT.
Copyright 2004 John Wiley & Sons, Ltd.
Similar articles
-
Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S7-S14. doi: 10.1016/j.jalz.2007.10.007. Epub 2007 Dec 21. Alzheimers Dement. 2008. PMID: 18632005
-
Treatment possibilities of Alzheimer's disease.Neuropsychopharmacol Hung. 2004 Dec;6(4):200-9. Neuropsychopharmacol Hung. 2004. PMID: 15825676 Review.
-
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.Alzheimers Dement. 2009 Mar;5(2):133-6. doi: 10.1016/j.jalz.2009.01.006. Alzheimers Dement. 2009. PMID: 19328443
-
The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50. doi: 10.1093/jnci/djh320. J Natl Cancer Inst. 2004. PMID: 15572756 Clinical Trial.
-
Vitamin C and vitamin E for Alzheimer's disease.Ann Pharmacother. 2005 Dec;39(12):2073-80. doi: 10.1345/aph.1E495. Epub 2005 Oct 14. Ann Pharmacother. 2005. PMID: 16227450 Review.
Cited by
-
Regulation and function of selenoproteins in human disease.Biochem J. 2009 Jul 29;422(1):11-22. doi: 10.1042/BJ20090219. Biochem J. 2009. PMID: 19627257 Free PMC article. Review.
-
Age-expanded normative data for the Ruff 2&7 Selective Attention Test: evaluating cognition in older males.Clin Neuropsychol. 2012;26(5):751-68. doi: 10.1080/13854046.2012.690451. Epub 2012 May 31. Clin Neuropsychol. 2012. PMID: 22651854 Free PMC article.
-
Optimizing parameters in clinical trials with a randomized start or withdrawal design.Comput Stat Data Anal. 2014 Jan 1;69:101-113. doi: 10.1016/j.csda.2013.07.013. Comput Stat Data Anal. 2014. PMID: 24159249 Free PMC article.
-
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE).JAMA Neurol. 2017 May 1;74(5):567-573. doi: 10.1001/jamaneurol.2016.5778. JAMA Neurol. 2017. PMID: 28319243 Free PMC article. Clinical Trial.
-
The impact of dementia prevalence on the utility of the AD8.Brain. 2012 Jan;135(Pt 1):e203; author reply e204. doi: 10.1093/brain/awr135. Epub 2011 Jun 8. Brain. 2012. PMID: 21653541 Free PMC article. No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical